Alert Data News | Business | Companies | UK | Pharmaceuticals

AstraZeneca PLC

Mon, 06 Feb 2012 09:30:46 +0000

7,300 job losses - 2% fall in revenues - competitive pressures
AstraZeneca is reducing headcount by 7,300 across its operations after revenue fell 2% to £22.2bn. Revenue in Western Europe fell 11% due to increased competition from generic drugs. It is not known which sites will be affected by the job cuts. The restructuring is expected to reduce costs and increase flexibility in functional areas.

AstraZeneca PLC

Mon, 06 Feb 2012 08:00:05 +0000

Revenue down 2% - Profit down 4% - 61700 Employees
AstraZeneca reorted revenue for the full year was down 2% at constant exchange rates at $33,591 million. Strong double-digit sales growth for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10%. Revenue performance reflects the loss of nearly $2 billion of revenue from generic competition, as well as a further $1 billion lost to the impact of government price interventions. David Brennan is Chief Executive Officer

GlaxoSmithKline PLC

Tue, 31 Jan 2012 12:00:02 +0000

Changes to Board - New Chairs appointed - Non-Executive Directors appointed and step down
GlaxoSmithKline plc has reported that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp, currently members of the GSK Board, will not stand for re-election to the Board at the Annual General Meeting (AGM) taking place in 2013. Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009. Judy Lewent will succeed Tom de Swaan as Chair of the Audit and Risk Committee with effect from January 2013. Ms Lewent has been a member of the Audit and Risk Committee since April 2011. In addition, Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director at the close of GSKs AGM in 2013. James Murdoch has also decided not to stand for re-election to the Board at GSKs AGM in 2012. Sir Christopher Gent is Chairman of GSK.

Abbott Laboratories Limited

Fri, 27 Jan 2012 14:00:02 +0000

Business expansion - Sales rise by 4.1% - Seven new products launched
Healthcare company Abbott Laboratories Limited, has recorded a 4.1% rise in sales to $10.4 billion. New markets represented approximately 25% of total sales at $2.5 billion. The global company has a UK base in Maidenhaed, Berkshire. In 2011, Abbott continued to expand its business and launched several new products or indications across their Pharmaceuticals, Medical Products, Nutritionals and Diagnostics businesses. Miles D. White is Chairman and Chief Executive Officer of Abbot Laboratories Limited.

PZ Cussons PLC

Fri, 27 Jan 2012 08:00:03 +0000

Half Yearly Report - Revenue up 10% to £414m, Operating Profit down 12.8% to £40.1m
PZ Cussons, a consumer products group in Europe, Asia and Africa, announces recorded interim results for the six months ended 30 November 2011. Revenue up 10.5% to £414.0m, operating profit down 12.8% to £40.1m. Richard Harvey is Chairman.

Alliance Boots Holdings Limited

Fri, 20 Jan 2012 09:05:48 +0000

Sales up 4.1% - Group revenue rises 14.1%
Alliance Boots, the Chemist chain, has recorded like-for-like sales growth of 4.1% in the five weeks to the end of December 2011. Group revenue increased by 14.1% compared to 2010. Stefano Pessina is Executive Chairman.

Alliance Pharma Plc

Mon, 16 Jan 2012 08:00:05 +0000

Alliance Pharma Plc - Pre-Close Trading Update
APH - speciality pharmaceutical company, announces its pre-close trading update for the year ended 31 December 2011. The Board expects to report turnover for 2011 of around £46m and for pre-tax profits to be in line with market expectations. Sales of Hydromol and ImmuCystTM continued to grow ...

GlaxoSmithKline PLC

Thu, 12 Jan 2012 09:20:08 +0000

£1.46 million Research and Development grant received - 25 new jobs
Glaxosmithkline in Montrose, Scotland has been awarded a £1.46 million Research and Development grant from Scottish Enterprise. The grant will help develop the site as a new product development facility and create up to 25 new jobs and safeguard others as a result. Andy Ross is Glaxosmithkline Montrose Site Director.

Bristol-Myers Squibb Pharmaceuticals Limited

Wed, 11 Jan 2012 09:49:46 +0000

Pharmaceutical company extends contract with BT
American pharmaceutical company, Bristol-Myers Squibb, has extended a major network services contract with BT for six years. The contract covers wide and local area network services, remote access, voice and telephony, as well as compliance management and security for all of the company's global locations. Rick Yborra is Vice President of Network and Hosting at Bristol-Myers Squibb.

Bristol-Myers Squibb Pharmaceuticals Limited

Wed, 11 Jan 2012 08:13:50 +0000

Inhibitex acquired - Company investment - Long term growth
Pharmaceuticals company Bristol-Myers Squibb has signed a definitive agreement to acquire Inhibitex for an aggregate purchase price of around $2.5bn. The acquisition represents an important investment in the long-term growth of the company.